Magnesium sulfate in severe preeclampsia: shorter course is safe, cost-effective

  • Unwaha EA & al.
  • Int J Gynaecol Obstet
  • 12 Dec 2019

  • International Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • 12 hours of postpartum intravenous magnesium sulfate is as safe as 24 hours of magnesium sulfate.

Why this matters

  • Preeclampsia affects 8% of pregnancies worldwide.
  • The minimum effective amount of intravenous dosing will help reduce cost and minimise monitoring.

Key results

  • No incidence of seizures during the study.
  • No differences in maternal or foetal outcome or number of days of maternal admission between groups.
  • Cost analysis was not performed.

Study design

  •  
  • Study outcomes included seizures, adverse maternal effects, neonatal survival, and admission to the ICU.
  • Funding: None disclosed.

Limitations

  • Single-site study.
  • Small numbers in the study.